InterStim Treatment for OAB in Sherman Oaks, CA
Cheif Medical Officer at Genesis Healthcare, Dr. Richard David is a board-certified urologist highly trained in using the InterStim system to treat overactive bladder. Many patients drive from Encino, Bel Air, or Studio City to recieve the latest in minimally invasive overactive bladder treatment at Genesis Healthcare. Dr. David will take the time to provide you with a comprehensive diagnosis to help determine if InteStime is right for you. Call (818) 990-5020 to schedule an appointment at our office in Sherman Oaks, CA.
Medtronic Bladder Control Therapy Delivered by The InterStimTM System
Evidence suggests that breakdowns in the bladder-brain communication pathway may be a root cause of OAB and non-obstructive urinary retention.1,2,3 That’s why conventional treatments may not produce the results you want – they don’t directly target this miscommunication. Unlike conventional treatments, the Medtronic InterStim systems gently stimulate the sacral nerves in the pelvic area that control the bladder.4,5 This may help restore* bladder-brain communication and reduce symptoms.
Get more control with the InterStim Systems6,7
- 84% satisfaction among those who use it 8
- 3X greater improvements in OAB quality of life9
- 82% of people achieved success** at 5 years6
- Only therapy that lets you see if it works before you and your doctor decide
- More than 350,000 people worldwide have chosen the Medtronic InterStim systems for more control6,7 and long-lasting relief
Recharge-free and rechargeable options let you choose the right device for your lifestyle
In addition to risks related to surgery, complications can include pain at the implant sites, new pain, infection, lead (thin wire) movement/migration, device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation (sometimes described as a jolting or shocking feeling). Talk with your doctor about ways to minimize these risks.
Is InterStim Right for You?
You may be a good candidate for Medtronic Bladder Control Therapy delivered by the InterStim systems if:
- You have significant OAB symptoms or non-obstructive urinary retention
- You’ve tried lifestyle changes and oral medications
- These therapies haven’t given you the relief you want
Say yes to the test
Take back control with an evaluation for an InterStim system
Unlike other bladder control treatments, this therapy lets you try it first with an evaluation – like a test run, not a long-term commitment.
Here’s how it works:
- The simple test starts at your doctor’s office or an outpatient center.
- A lead (thin wire) is inserted in the upper part of your buttock.
- The lead attaches to a small external device worn discreetly under your clothes.
- Stop, start, or adjust the therapy settings, with an easy-to-use programmer that resembles a smartphone.
- Go about most of your regular activities for 3 to 14 days
- Track your symptoms to see if they improve
Complications can occur with the evaluation, including movement of the wire, technical problems with the device, and some temporary pain. Your doctor or nurse will show you how to use the system and inform you of any activity restrictions and other precautions related to the evaluation.
Get more personalized treatment options
After your test, talk to your doctor about the results. Together, you can choose a powerful and personalized solution for your long-term care. Your evaluation device can be replaced with an implantable device called a neurostimulator during a short, outpatient procedure.
Bladder control therapy has risks similar to any surgical procedure. The most common adverse events experienced during clinical studies include pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms. Discuss these potential risks and benefits with your doctor.
*Restored function defined as a 50% or greater reduction in dysfunctional voiding symptoms from baseline
** Numbers reflect completers analysis defined as patients with diary data at baseline and 12 months (n=220). Clinical success was 82% at 12 months using the modified completers analysis (subjects who either had a baseline and 12-month evaluation or withdrew early due to device-related reasons and are considered failures). Success defined as a 50% or greater reduction in your troublesome bladder symptoms.
1. Dasgupta R. Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005; 174:2268-2272
2. Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005; 174:1862-1867.
3. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466-474.
4. Kenefick NJ, Emmanuel A, Nicholls RJ. Effect of sacral nerve stimulation on autonomic nerve function. British Journal of Surgery. 2003;90:1256-1260.
5. Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013;100:959–968.
6. Siegel S, Noblett K, Mangel J, et al. Five-year follow-up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. The Journal of Urology 2018; Volume 199(1), 229–236.
7. Medtronic InterStim Therapy Clinical Summary (2018)
8. Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007; 26:213-217.
9. Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015; 34:224–230. DOI: 10.1002/nau.22544.